Validation of Group B Borderline Resectable Pancreatic Cancer: Retrospective Analysis
Gut and Liver
;
: 557-562, 2014.
Artículo
en Inglés
| WPRIM
| ID: wpr-91770
ABSTRACT
BACKGROUND/AIMS:
Among borderline resectable pancreatic cancer (BRPC), group B BRPC patients have findings that are suggestive but not diagnostic of metastasis. In this study, we attempted to validate whether group B could truly be categorized as a borderline resectable group.METHODS:
We placed the BRPC patients into group A or group B. The survival outcomes were compared between the groups.RESULTS:
A total of 53 patients with pancreatic adenocarcinoma was classified as either group A or B borderline resectable. In group A, 23 (60.5%) of 38 patients underwent pancreatectomy after concurrent chemoradiotherapy or chemotherapy, but in group B, only five (33.3%) of 15 patients underwent pancreatectomy, mainly because of the progression of suspected distant metastasis. There was a significant difference in overall survival (OS) between group A and B patients (median OS, 21.2 months vs 10.2 months, respectively; p=0.007). Of the patients who underwent pancreatectomy, group B had a higher recurrence rate compared to group A (recurrence rate 11 of 23 patients [47.8%] vs five of five patients [100%], respectively; p=0.033).CONCLUSIONS:
This report is the first to validate the definition of BPRC. Group B had much worse outcomes, and whether group B BRPC can be categorized as BRPC together with group A is questionable.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Pancreatectomía
/
Neoplasias Pancreáticas
/
Adenocarcinoma
/
Estudios Retrospectivos
/
Resultado del Tratamiento
/
Quimioradioterapia
/
Metástasis de la Neoplasia
/
Recurrencia Local de Neoplasia
Tipo de estudio:
Estudio observacional
Límite:
Adulto
/
Anciano
/
Aged80
/
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Gut and Liver
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS